Annovis Bio Inc. announced plans to begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson's disease. The study aims to enroll 500 participants, including both previous Annovis clinical trial participants and patients who have been receiving deep brain stimulation $(DBS)$ for at least 12 months. The study will monitor patients over 36 months and collect skin and plasma biomarkers to enhance understanding of disease progression. The announcement outlines future research; no specific scientific results have been presented yet.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604831-en) on December 18, 2025, and is solely responsible for the information contained therein.